Pitolisant Hydrochloride

盐酸替洛利生

Report date: 2026/03/31 20:00:21
NMEFirst In Class

Base Information

Drug NamePitolisant Hydrochloride
Drug Alias Name匹立桑特TiprolisantpitolisantWakixOZAWADE +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistamine H3 receptor antagonistsHistamine H3 receptor inverse agonists
TargetsHistamine H3 receptor
Therapy Area/IndicationsSchizophreniaAutism Spectrum DisorderAlcohol Drinking +[16] 
Global Approved IndicationsNarcolepsy
Approved Indications in ChinaNarcolepsy
Original Approved Country/TerritoryEU
Original Approved Date2016/03/31
Country/TerritoryBulgariaCanadaUnited States +[16] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBioprojet PharmaInserm
China Registration ClassN/A

Develop Information

Active CompaniesBioProjetChina Resources Sanjiu Medical & Pharmaceutical Co LtdBioprojet Pharma +[7] 
Inactive CompaniesHigh Point Clinical Trials CenterUniversity of Texas Southwestern Medical CenterNa Pharma Ltd +[4] 
Active IndicationsAutism Spectrum DisorderCataplexyNarcolepsy +[5] 
Inactive IndicationsSchizophreniaAlcohol DrinkingAlcoholism +[11] 

Other Information

ATC CodeN07XX11
Related LinksWikipediaDrugBankKEGG